Related references
Note: Only part of the references are listed.Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study
Thierry Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Targeting GPC3(high) cancer-associated fibroblasts sensitizing the PD-1 blockage therapy in gastric cancer
Dinuo Li et al.
ANNALS OF MEDICINE (2023)
Targeting tumor exosomal circular RNA cSERPINE2 suppresses breast cancer progression by modulating MALT1-NF-?B-IL-6 axis of tumor-associated macrophages
Boxuan Zhou et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2023)
CREBZF mRNA nanoparticles suppress breast cancer progression through a positive feedback loop boosted by circPAPD4
Boxuan Zhou et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2023)
PKM2/STAT1-mediated PD-L1 upregulation on neutrophils during sepsis promotes neutrophil organ accumulation by serving an anti-apoptotic role
Yinjiaozhi Li et al.
JOURNAL OF INFLAMMATION-LONDON (2023)
Relationships of tumor differentiation and immune infiltration in gastric cancers revealed by single-cell RNA-seq analyses
Xin Zhou et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2023)
Prognostic role and clinical significance of tumor-infiltrating lymphocyte (TIL) and programmed death ligand 1 (PD-L1) expression in gastric cancer: a systematic review and meta-analysis
Juan Ren et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2023)
Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients
Hyun Cheol Chung et al.
CANCER (2022)
Crosstalk between cancer-associated fibroblasts and immune cells in peritoneal metastasis: inhibition in the migration of M2 macrophages and mast cells by Tranilast
Yusuke Nakamura et al.
GASTRIC CANCER (2022)
Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study
Kensei Yamaguchi et al.
GASTRIC CANCER (2022)
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET ONCOLOGY (2022)
Tumor-derived exosomes induce PD1+ macrophage population in human gastric cancer that promotes disease progression (vol 7, 41, 2018)
Furong Wang et al.
ONCOGENESIS (2022)
Circulating PD-L1 is associated with T cell infiltration and predicts prognosis in patients with CRLM following hepatic resection
Xiuxing Chen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)
Expression of programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand (PD-L1) in adenocarcinomas of the gastroesophageal junction change significantly after neoadjuvant treatment
Gerd Jomrich et al.
EJSO (2022)
Tumor-derived IL-8 facilitates lymph node metastasis of gastric cancer via PD-1 up-regulation in CD8+ T cells
Xiang Li et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial
Charles S. Fuchs et al.
GASTRIC CANCER (2022)
A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer
Hirotaka Hasegawa et al.
GASTRIC CANCER (2022)
The current management and biomarkers of immunotherapy in advanced gastric cancer
Xiaojing Chang et al.
MEDICINE (2022)
LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer
Dan-Dan Shen et al.
MOLECULAR CANCER (2022)
Intratumoral expression analysis reveals that OX40 and TIM-3 are prominently expressed and have variable associations with clinical outcomes in high grade serous ovarian cancer
Nicole E. James et al.
ONCOLOGY LETTERS (2022)
Depletion of tumor associated macrophages enhances local and systemic platelet-mediated anti-PD-1 delivery for post-surgery tumor recurrence treatment
Zhaoting Li et al.
NATURE COMMUNICATIONS (2022)
Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer
Yuezong Bai et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study
Haiping Jiang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials
Yoon-Koo Kang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Liver tumour immune microenvironment subtypes and neutrophil heterogeneity
Ruidong Xue et al.
NATURE (2022)
The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma
Zhihao Lu et al.
GASTRIC CANCER (2022)
Complete remission of alpha-fetoprotein-producing gastric cancer by combined tislelizumab-apatinib treatment of a patient with proficient mismatch repair: a case report
Jinyu Xiang et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2022)
A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer
Choong-kun Lee et al.
NATURE COMMUNICATIONS (2022)
Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trial
Yuping Yin et al.
FRONTIERS IN ONCOLOGY (2022)
Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy
Hongzhen Cai et al.
BIOMARKER RESEARCH (2022)
Parallel single-cell and bulk transcriptome analyses reveal key features of the gastric tumor microenvironment
Boxi Kang et al.
GENOME BIOLOGY (2022)
Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody
Lin Zhang et al.
CANCER CONTROL (2022)
Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer
Kohei Yamashita et al.
BRITISH JOURNAL OF CANCER (2021)
Advances in clinical immunotherapy for gastric cancer
Kexin Li et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2021)
PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer
Camille Evrard et al.
DIGESTIVE AND LIVER DISEASE (2021)
MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma
Daniel V. T. Catenacci et al.
FUTURE ONCOLOGY (2021)
Regulation of PD-L1 expression in the tumor microenvironment
Ming Yi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
The crosstalk between H. pylori virulence factors and the PD1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer
Elif Merve Aydin et al.
IMMUNOLOGY LETTERS (2021)
PD-1 inhibitor combined with apatinib modulate the tumor microenvironment and potentiate anti-tumor effect in mice bearing gastric cancer
Hao Chen et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2021)
Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells
Simon J. Dovedi et al.
CANCER DISCOVERY (2021)
M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer
Rui Zhao et al.
ONCOIMMUNOLOGY (2021)
Helicobacter pylori Virulence Factors-Mechanisms of Bacterial Pathogenicity in the Gastric Microenvironment
Jacek Baj et al.
CELLS (2021)
Current treatment and recent progress in gastric cancer
Smita S. Joshi et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice
Woosook Kim et al.
GASTROENTEROLOGY (2021)
Identification of functional methylated CpG loci in PD-L1 promoter as the novel epigenetic biomarkers for primary gastric cancer
Mohammad Amini et al.
GENE (2021)
The circular RNA circDLG1 promotes gastric cancer progression and anti-PD-1 resistance through the regulation of CXCL12 by sponging miR-141-3p
Dong-Liang Chen et al.
MOLECULAR CANCER (2021)
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
Yelena Y. Janjigian et al.
NATURE (2021)
KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma
Josep Tabernero et al.
FUTURE ONCOLOGY (2021)
Exploring the interactions between Helicobacter pylori (Hp) infection and other risk factors of gastric cancer: A pooled analysis in the Stomach cancer Pooling (StoP) Project
Giulia Collatuzzo et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Ronan J. Kelly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
MicroRNA Changes in Gastric Carcinogenesis: Differential Dysregulation during Helicobacter pylori and EBV Infection
Christian Prinz et al.
GENES (2021)
Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials
Joseph Chao et al.
JAMA ONCOLOGY (2021)
Tubeimoside-1 induces TFEB-dependent lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting mTOR
Xiaojia Liu et al.
ACTA PHARMACEUTICA SINICA B (2021)
Gastric epithelial attachment of Helicobacter pylori induces EphA2 and NMHC-IIA receptors for Epstein-Barr virus
Sintayehu Fekadu et al.
CANCER SCIENCE (2021)
Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations
Edouard Dantoing et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Yelena Y. Janjigian et al.
LANCET (2021)
MiR-375 reduces the stemness of gastric cancer cells through triggering ferroptosis
Haiwei Ni et al.
STEM CELL RESEARCH & THERAPY (2021)
Adaptive NK Cell Therapy Modulated by Anti-PD-1 Antibody in Gastric Cancer Model
Shahrokh Abdolahi et al.
FRONTIERS IN PHARMACOLOGY (2021)
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer
Marcelo Negrao et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Expression of the immune checkpoint receptors PD-1, LAG3, and TIM3 in the immune context of stage II and III gastric cancer by using single and chromogenic multiplex immunohistochemistry
Yujun Park et al.
ONCOIMMUNOLOGY (2021)
Role of PD-L1 Expression during the Progression of Submucosal Gastric Cancer
Yasunari Ubukata et al.
ONCOLOGY (2021)
Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Ronan J. Kelly et al.
CLINICAL CANCER RESEARCH (2020)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Single-Cell Genomic Characterization Reveals the Cellular Reprogramming of the Gastric Tumor Microenvironment
Anuja Sathe et al.
CLINICAL CANCER RESEARCH (2020)
Differential prognostic impact of CD8+ T cells based on human leucocyte antigen I and PD-L1 expression in microsatellite-unstable gastric cancer
Yoonjin Kwak et al.
BRITISH JOURNAL OF CANCER (2020)
Immune checkpoint signaling and cancer immunotherapy
Xing He et al.
CELL RESEARCH (2020)
Epstein-Barr virus-encoded miR-BART5-5p upregulates PD-L1 through PIAS3/pSTAT3 modulation, worsening clinical outcomes of PD-L1-positive gastric carcinomas
Chan Jin Yoon et al.
GASTRIC CANCER (2020)
Immune checkpoint inhibitor-related dermatologic adverse events
Amaris N. Geisler et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
Yelena Y. Janjigian et al.
LANCET ONCOLOGY (2020)
Are Immunohistochemical Markers Useful in Phenotypic Gastric Cancer Classification?
Federica Di Pinto et al.
ONCOLOGY (2020)
The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target
V Gambardella et al.
CANCER TREATMENT REVIEWS (2020)
An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells
Shogo Kumagai et al.
IMMUNITY (2020)
CXCL5 promotes gastric cancer metastasis by inducing epithelial-mesenchymal transition and activating neutrophils
Zheying Mao et al.
ONCOGENESIS (2020)
Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
Lin Shen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
PD-1 does not mark tumor-infiltrating CD8+T cell dysfunction in human gastric cancer
Yang Shen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5
Yang Liu et al.
ACTA PHARMACEUTICA SINICA B (2020)
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
Susan M. Domchek et al.
LANCET ONCOLOGY (2020)
Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial
Haiping Jiang et al.
BMC CANCER (2020)
Natural killer cells in cancer biology and therapy
Song-Yang Wu et al.
MOLECULAR CANCER (2020)
The impaired anti-tumoral effect of immune surveillance cells in the immune microenvironment of gastric cancer
Xueke Fan et al.
CLINICAL IMMUNOLOGY (2020)
Immune suppressed tumor microenvironment by exosomes derived from gastric cancer cells via modulating immune functions
Juan Liu et al.
SCIENTIFIC REPORTS (2020)
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Kohei Shitara et al.
JAMA ONCOLOGY (2020)
Tumor-promoting macrophages prevail in malignant ascites of advanced gastric cancer
Hye Hyeon Eum et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2020)
Exosomal miRNA-16-5p Derived From M1 Macrophages Enhances T Cell-Dependent Immune Response by Regulating PD-L1 in Gastric Cancer
Zhengtian Li et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Establishment of an immune microenvironment-based prognostic predictive model for gastric cancer
Luying Wan et al.
LIFE SCIENCES (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
IDO1 Expression Is Associated With Immune Tolerance and Poor Prognosis in Patients With Surgically Resected Esophageal Cancer
Yuki Kiyozumi et al.
ANNALS OF SURGERY (2019)
EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions
Sho Sasaki et al.
GASTRIC CANCER (2019)
KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer
Yung-Jue Bang et al.
FUTURE ONCOLOGY (2019)
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
Yung-Jue Bang et al.
GASTRIC CANCER (2019)
Autophagy inhibition enhances PD-L1 expression in gastric cancer
Xiaojuan Wang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Viral loads correlate with upregulation of PD-L1 and worse patient prognosis in Epstein-Barr Virus-associated gastric carcinoma
Atsuhito Nakayama et al.
PLOS ONE (2019)
Increased Programmed Death-Ligand 1 is an Early Epithelial Cell Response to Helicobacter pylori Infection
Loryn Holokai et al.
PLOS PATHOGENS (2019)
Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis
Cong Chen et al.
ONCOIMMUNOLOGY (2019)
Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial
Hyun Cheol Chung et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
Mauro Poggio et al.
CELL (2019)
Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer
In-Hye Ham et al.
MOLECULAR CANCER (2019)
First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors
Kohei Shitara et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Immune cell PD-L1 co-localizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy
Yuting Liu et al.
CLINICAL CANCER RESEARCH (2019)
Mechanisms Controlling PD-L1 Expression in Cancer
Jong-Ho Cha et al.
MOLECULAR CELL (2019)
Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial
Toshihiko Doi et al.
GASTRIC CANCER (2019)
Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer
Chao Lin et al.
GUT (2019)
From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer
David Vrana et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Tumor-associated neutrophils induce EMT by IL-17a to promote migration and invasion in gastric cancer cells
Sen Li et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Programmed death-ligand 1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer
Masahiko Amatatsu et al.
CANCER SCIENCE (2018)
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Julian A. Marin-Acevedo et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara et al.
LANCET (2018)
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
Seung Tae Kim et al.
NATURE MEDICINE (2018)
Tumor-associated macrophages-derived exosomes promote the migration of gastric cancer cells by transfer of functional Apolipoprotein E
Peiming Zheng et al.
CELL DEATH & DISEASE (2018)
NF-κB/miR-223-3p/ARID1A axis is involved in Helicobacter pylori CagA-induced gastric carcinogenesis and progression
Fenghua Yang et al.
CELL DEATH & DISEASE (2018)
STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
Jung-Mao Hsu et al.
NATURE COMMUNICATIONS (2018)
Immunoclassification characterized by CD8 and PD-L1 expression is associated with the clinical outcome of gastric cancer patients
Weili Wang et al.
Oncotarget (2018)
Exosomes Released by Gastric Cancer Cells Induce Transition of Pericytes Into Cancer-Associated Fibroblasts
Xiaofei Ning et al.
MEDICAL SCIENCE MONITOR (2018)
Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation
Genevieve P. Hartley et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs et al.
JAMA ONCOLOGY (2018)
Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
Y. -J. Bang et al.
ANNALS OF ONCOLOGY (2018)
Helicobacter pylori-induced exosomal MET educates tumour-associated macrophages to promote gastric cancer progression
Ying Che et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2018)
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
Yelena Y. Janjigian et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Association between Helicobacter pylori, Epstein-Barr virus, human papillomavirus and gastric adenocarcinomas
Carolina Rosal Teixeira de Souza et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Prognostic impact of CD44-positive cancer stem-like cells at the invasive front of gastric cancer
Hirokazu Kodama et al.
BRITISH JOURNAL OF CANCER (2017)
Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma
Elizabeth D. Thompson et al.
GUT (2017)
Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
Ruea-Yea Huang et al.
ONCOIMMUNOLOGY (2017)
Polyamine-and NADPH-dependent generation of ROS during Helicobacter pylori infection: A blessing in disguise
Alain P. Gobert et al.
FREE RADICAL BIOLOGY AND MEDICINE (2017)
Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway
Ting-ting Wang et al.
GUT (2017)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET (2017)
DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
Hiro Sato et al.
NATURE COMMUNICATIONS (2017)
Immunotherapeutic Strategies for Gastric Carcinoma: A Review of Preclinical and Clinical Recent Development
Mohamed Abozeid et al.
BIOMED RESEARCH INTERNATIONAL (2017)
Tumor-Associated Monocytes/Macrophages Impair NK-Cell Function via TGFβ1 in Human Gastric Cancer
Liu-sheng Peng et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
Renee N. Donahue et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
IFNγ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma
Ji Wook Moon et al.
SCIENTIFIC REPORTS (2017)
Tumor-infiltrating CD4+ T cells in patients with gastric cancer
Long Yuan et al.
CANCER CELL INTERNATIONAL (2017)
Initiation and Maintenance of Gastric Cancer: A Focus on CD44 Variant Isoforms and Cancer Stem Cells
Yana Zavros
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY (2017)
Tumor-associated macrophages of the M2 phenotype contribute to progression in gastric cancer with peritoneal dissemination
Takahisa Yamaguchi et al.
GASTRIC CANCER (2016)
Arginase 2 deletion leads to enhanced M1 macrophage activation and upregulated polyamine metabolism in response to Helicobacter pylori infection
Dana M. Hardbower et al.
AMINO ACIDS (2016)
Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study
S. Kanda et al.
ANNALS OF ONCOLOGY (2016)
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Antoni Ribas et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Kei Muro et al.
LANCET ONCOLOGY (2016)
Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer
Jin Won Kim et al.
GASTRIC CANCER (2016)
Nitrative and oxidative DNA damage in infection-related carcinogenesis in relation to cancer stem cells
Shosuke Kawanishi et al.
GENES AND ENVIRONMENT (2016)
The gut microbiome as a target for regulatory T cell-based immunotherapy: induction of regulatory lymphocytes by oral administration of anti-LPS enriched colostrum alleviates immune mediated colitis
Ami Ben Ya ' acov et al.
BMC GASTROENTEROLOGY (2015)
TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients
Joe-Marc Chauvin et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
Nan Chen et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
Razvan Cristescu et al.
NATURE MEDICINE (2015)
Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo
Julia Cuende et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model
Ruea-Yea Huang et al.
ONCOTARGET (2015)
Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas
Suling J. Lin et al.
GUT (2015)
Helicobacter pylori infection and stem cells at the origin of gastric cancer
E. Bessede et al.
ONCOGENE (2015)
Comprehensive molecular characterization of gastric adenocarcinoma
Adam J. Bass et al.
NATURE (2014)
Identification of Molecular Subtypes of Gastric Cancer With Different Responses to PI3-Kinase Inhibitors and 5-Fluorouracil
Zhengdeng Lei et al.
GASTROENTEROLOGY (2013)
Th17 cell development: from the cradle to the grave
Luis A. Zuniga et al.
IMMUNOLOGICAL REVIEWS (2013)
The Th17 family: flexibility follows function
Rajatava Basu et al.
IMMUNOLOGICAL REVIEWS (2013)
Epstein Barr Virus and Helicobacter pylori Co-Infection Are Positively Associated with Severe Gastritis in Pediatric Patients
Maria G. Cardenas-Mondragon et al.
PLOS ONE (2013)
Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation
Nikolaos Patsoukis et al.
SCIENCE SIGNALING (2012)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Janis M. Taube et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Evidence Implicating the Ras Pathway in Multiple CD28 Costimulatory Functions in CD4+ T Cells
Sujit V. Janardhan et al.
PLOS ONE (2011)
Premature Terminal Exhaustion of Friend Virus-Specific Effector CD8+ T Cells by Rapid Induction of Multiple Inhibitory Receptors
Shiki Takamura et al.
JOURNAL OF IMMUNOLOGY (2010)
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
Junko Matsuzaki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: N1 versus N2 TAN
Zvi G. Fridlender et al.
CANCER CELL (2009)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
Manish J. Butte et al.
IMMUNITY (2007)
Expression of B7-H1 on gastric epithelial cells:: Its potential role in regulating T cells during Helicobacter pylori infection
Soumita Das et al.
JOURNAL OF IMMUNOLOGY (2006)
Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance
Changping Wu et al.
ACTA HISTOCHEMICA (2006)